Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 12, 2008, Pages 1393-1400

  Moreno, S ^a,d,e   Jarrin, I ^b,c,d   Iribarren, J A ^d,o   Perez Elias M J ^a   Viciana, P ^e   Parra, J ^f,g   Gomez Sirvent, J L ^g,k,q   Lopez Aldeguer, J ^h   Gutierrez, F ^i,s   Blanco, J R ^e,j   Vidal, F ^h,k   Leal, M ^d   Rodriguez Arenas M A ^l   Del Amo, Julia ^b,d,m,n   Arrizabalaga, J ^o   Aramburu, M J ^o   Camino, X ^o   Rodriguez Arrondo, F ^o   Von Wichmann, M A ^o   Antela, A ^e   Casado, J L ^e   Dronda, F ^e   Moreno, A ^e   Perez Elias, M J ^e   Fernandez, P V ^p   Lopez Cortes, L F ^p   Gonzalez, M T ^p   Mata, R ^p   Pena A ^g   Munoz L ^g   Aleman Valls, Ma R ^k,q   Del Mar Alonso Socas, Ma ^k,q   Caizadilla, C H ^k,q   Peraire, J ^h   Veloso, S ^h   Vilades C ^h   Calabuig, E ^r   Lacruz, J ^r   Cuellas, S ^r   Montoro, M ^r   Blanes, M ^r   Aldeguer, J L ^r   Padilla, S ^s   Bernal, E ^s   Masia M ^s   Oteo, J A ^e   Ibarra, V ^e   Noval, M L ^t   more..

^a UNIVERSITY OF ALCALÁ   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^j HOSPITAL SAN PEDRO   (Spain)

^k HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^l Centro de Salud Publica de Alicante   (Spain)

^m UNIVERSIDAD REY JUAN CARLOS   (Spain)

ⁿ CARLOS III INSTITUTE OF HEALTH   (Spain)

^o HOSPITAL RAMÓN Y CAJAL   (Spain)

^p Hospital Universitario de Granada

^q UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^r HÔPITAL DU BOCAGE   (France)

^s Department of Geriatric Medicine   (Spain)

^t Hospital General de Elche ^*

more..

Author keywords

HAART; Injecting drug users; TB HIV co infection; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; TUBERCULOSIS; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; RISK FACTORS; TUBERCULOSIS;

EID: 58049219739     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
2. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
3. Santoro-Lopes G, Felix de Pinho A, Harrison L H, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546.
4. Badri M, Wilson D, Wood R. Effect of highly antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
5. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2220-2226.
6. Kirk O, Gatell J M, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162: 865-872.
7. Jones J L, Hanson D L, Dworkin M S, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 14: 1985-1991.
8. Girardi E, Antonucci G, Vanacore P, et al. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24: 11-17.
9. Syler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172: 3-4.
10. Girardi E, Sabin C A, d'Arminio Monforte A and the Antiretroviral Therapy Cohort Collaboration. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-1782.
11. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long-term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
12. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992; 32: 668-672.
13. Centro Nacional de Epidemiología, Instituto de Salud Carlos III. Vigilancia epidemiológica del sida en España. Bol Epidemiol Semanal 2006; 14: 133-144.
14. Castilla J, Gutierrez A, Guerra L, et al. Pulmonary and extrapulmonary tuberculosis at AIDS diagnosis in Spain: epidemiological differences and implications for control. AIDS 1997; 11: 1583-1588.
15. European Commission (DG Sanco), Institut de Veille Sanitaire. Surveillance of tuberculosis in Europe. Annual reports 2004. St Maurice, France: EuroTB. http://www.eurotb.org/ Accessed December 2006.
16. Castilla Catalan J, Guerra Romero L, Canon Campos J, et al. Reduction of the incidence of tuberculosis following the introduction of new treatments against HIV. Rev Clin Esp 1999; 199: 186-187.
17. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 2007; 21: 2521-2527.
18. Rodríguez-Arenas M A, Jarrín I, del Amo J, et al. Delay in the initiation of HAART, poorer virological response and higher mortality among HIV infected injecting drug users in Spain. AIDS Res Hum Retroviruses 2006; 2: 715-723.
19. Hernan M A, Robins J M. Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006; 60: 578-586.
20. Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA). Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-1521.
21. Navas E, Martín Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162: 97-99.
22. Lawn S D, Bekker L G, Millar R F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373.
23. Diez M, Bleda M J, Alcaide J, et al. Determinants of patient delay among tuberculosis cases in Spain. Eur J Public Health 2004; 14: 151-155.
24. Holmes C B, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998; 2: 96-104.
25. Diez M, Diaz A, Bleda M J, et al. Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain. Int J Tuberc Lung Dis 2007; 11: 1196-1202.
26. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102.